Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.
- Resource Type
- Academic Journal
- Authors
- Tran HT; Department of Thoracic Head & Neck Medical Oncology.; Heeke S; Department of Thoracic Head & Neck Medical Oncology.; Sujit S; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston.; Vokes N; Department of Thoracic Head & Neck Medical Oncology.; Zhang J; Department of Thoracic Head & Neck Medical Oncology.; Aminu M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston.; Lam VK; Department of Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore.; Vaporciyan A; Department of Thoracic and Cardiovascular Surgery.; Swisher SG; Department of Thoracic and Cardiovascular Surgery.; Godoy MCB; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, USA.; Cascone T; Department of Thoracic Head & Neck Medical Oncology.; Sepesi B; Department of Thoracic Head & Neck Medical Oncology.; Gibbons DL; Department of Thoracic Head & Neck Medical Oncology.; Wu J; Department of Thoracic Head & Neck Medical Oncology; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston.; Heymach JV; Department of Thoracic Head & Neck Medical Oncology. Electronic address: jheymach@mdanderson.org.
- Source
- Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
- Subject
- Language
- English
Background: Predicting relapse and overall survival (OS) in early-stage non-small-cell lung cancer (NSCLC) patients remains challenging. Therefore, we hypothesized that detection of circulating tumor DNA (ctDNA) can identify patients with increased risk of relapse and that integrating radiological tumor volume measurement along with ctDNA detectability improves prediction of outcome.
Patients and Methods: We analyzed 366 serial plasma samples from 85 patients who underwent surgical resections and assessed ctDNA using a next-generation sequencing liquid biopsy assay, and measured tumor volume using a computed tomography-based three-dimensional annotation.
Results: Our results showed that patients with detectable ctDNA at baseline or after treatment and patients who did not clear ctDNA after treatment had a significantly worse clinical outcome. Integrating radiological analysis allowed the stratification in risk groups prognostic of clinical outcome as confirmed in an independent cohort of 32 patients.
Conclusions: Our findings suggest ctDNA and radiological monitoring could be valuable tools for guiding follow-up care and treatment decisions for early-stage NSCLC patients.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)